Follow
Bispecific Antibodies (BsAbs)
Bispecific Antibodies (BsAbs) are antibodies that can bind two different and independent cells or the particular antigenic determinant of the same antigen. BsAbs are used to kill tumor cells by changing cytotoxic immune effector cells. In order to do so, the antibodies use anti-body dependent cell -mediated cytotoxicity and other mechanisms placated by the effector cells.
What's Popular in Bispecific Antibodies (BsAbs)
-
APR 11, 2023Cancer
Monoclonal antibodies have revolutionized cancer therapy since their introduction as therapeutics in the field. To enhan ...Sponsored By: Sino BiologicalDEC 26, 2022Immunology
Almost every patient who gets myeloma and is treated with a standard therapy also experiences relapse. But researchers h ...Written By: Carmen LeitchJUN 06, 2022Immunology
Cancer can arise from a variety of aberrations that cause cells to divide uncontrollably, and form a tumor. The causes o ...Written By: Carmen LeitchOCT 26, 2021Immunology
Our immune system has developed an arsenal of sophisticated molecular weapons to defend us against the continuous barrag ...Written By: Tara FernandesNOV 22, 2017Drug Discovery & Development
The use of bispecific antibodies in cancer immunotherapiesWritten By: Courtney Schaal
APR 11, 2023
Cancer
Monoclonal antibodies have revolutionized cancer therapy since their introduction as therapeutics in the field. To enhan
...
Sponsored By:
Sino Biological
DEC 26, 2022
Immunology
Almost every patient who gets myeloma and is treated with a standard therapy also experiences relapse. But researchers h
...
Written By:
Carmen Leitch
JUN 06, 2022
Immunology
Cancer can arise from a variety of aberrations that cause cells to divide uncontrollably, and form a tumor. The causes o
...
Written By:
Carmen Leitch
OCT 26, 2021
Immunology
Our immune system has developed an arsenal of sophisticated molecular weapons to defend us against the continuous barrag
...
Written By:
Tara Fernandes
NOV 22, 2017
Drug Discovery & Development
The use of bispecific antibodies in cancer immunotherapies
Written By:
Courtney Schaal